Purpose

Glenoid version has been correlated with tears within the rotator cuff. Cuff tear arthropathy is an evolution of multiple unhealed tendons ultimately resulting in pseudoparalysis. Although several factors are critical to allow tendon healing, we have observed that there is less glenoid version in patients with cuff tear arthropathy. This was compared to those with osteoarthritis where rotator cuff tears are uncommon. We hypothesize that patients undergoing inverse prosthesis generally have a near neutral glenoid.

Purpose: The success of humeral head replacement following fracture is reliant on several factors, one of which is version. The correct humeral version (HV) is highly variable, and is patient and side dependent. In the setting of fracture, there is no intra-operative landmark to guide the surgeon as to the anatomic version. This study has examined computed tomography (CT) of the shoulder and compared the HV to the metaphyseal version (MV) to evaluate reliability in predicting the anatomic version.

Method: A retrospective review of 50 shoulder CT scans was carried out. Patients were excluded if the anatomy prevented HV or MV evaluation. The HV and MV was measured by 2 independent evaluators. Inter and intra-rater reliability was performed.

Results: There were 27 right and 23 left shoulder CT’s reviewed. The mean age of patients was 45.3 (range 13–85). The difference between the MV and HV was approximately 2.8 (95% CI 0.63–5.1). Inter and intra-rater reliability was 0.966 and 0.984, respectively.

Conclusion: Determining the version of the humeral head in the setting of fracture is difficult and highly inaccurate. The biceps groove has been previously cited as a landmark for arthroplasty position, however, given the anatomic variability, version may be miscalculated. We have demonstrated the medial calcar of the proximal humerus is within 3 degrees of the actual humeral head version. This CT guided approach is novel, reproducible and demonstrates excellent reliability. It is both accurate and consistent and may be successfully utilized in the setting where normal anatomic landmarks are absent, such as fracture.

Purpose: The reverse total shoulder arthroplasty (RTSA) has shown improvement in both pain control and function in recent studies. The purpose of this study was to prospectively analyze functional outcomes and strength in patients following the use of the Delta III prosthesis in a single center.

Method: Patients treated by one of two surgeons were prospectively evaluated following RTSA. An independent observer administered the Constant Score, SF-12, Shoulder Osteoarthritis (SOAQ), ASES, DASH questionnaires and patient satisfaction. Isometric strength testing was performed using the Powertrack II dynamometer. Follow-up for all patients was available up to 5 years following surgery.

Results: The Delta III RTSA was performed on 51 study patients (67% female, mean age 74 (SD=10)). Improvements following surgery were noted in Quality of life (SF-12 Physical Summary= 30 to 38); shoulder disability (SOAQ= 144 to 79; ASES 7 to 15; DASH= 61 to 46; Constant 21 to 56), Symptoms (SOAQ symptoms 40 to 22), Physical impairments as determined by strength (External rotation = 3 to 5 Nm, Abduction 4 to 10 Nm); and ROM (Flexion= 51 to 115°, abduction 45 to 106°); p< 0.05. All patients had follow up between 2–5 years. Satisfaction was high (86% extremely, 3% not at all).

Conclusion: Our data demonstrates significant improvements in quality of life, symptoms, patient satisfaction and disability with reduced and high at more than 2 years following RTSA. Novel to this study is improved objective evidence of strength in functional planes of motion. This is the first Canadian study to demonstrate such improvements in patients following RTSA.

The current standard of care in Calgary, Alberta for management of a ruptured Achilles tendon is surgical repair, typically performed following admission to hospital. The primary objective of this study was to compare the costs of hospital treatment and complications associated with the surgical repair of Achilles tendon ruptures between two groups of patients: Group One = patients enrolled in the randomised clinical trial (RCT) Multicentre Achilles Tendon Treatment Study (MATTS), Group Two = all other non-study patients.

This observational cohort study analyzed all patients surgically treated for Achilles tendon ruptures at Calgary area hospitals over a three-year period (October 2002–September 2005). Inclusion criteria: age eighteen to seventy years, acute rupture.

A total of two hundred and eighty-two patients met the inclusion criteria; thirty-three patients were included in Group One, two hundred and forty-nine patients in Group Two. In Group One, twenty-seven patients (82%) were treated as outpatients, five patients (15%) were ADOP-24hr, and one patient (3%) was admitted. In Group Two, twenty-seven patients (11%) were treated as outpatients, ninety-five patients (38%) were ADOP-24hr, and one hundred and twenty-seven patients (51%) were admitted. The total costs for patients treated as outpatients and requiring overnight stays in Group One were $18,408 and $7,419, respectively. In Group Two, the total cost for outpatients was $18,071 compared to $379,496 for non-study patients requiring overnight stay. If all overnight patients in each group were treated as outpatients, the total savings would be $235,545. There were no serious complications in Group One. In Group Two, complications included two cases of pulmonary embolus, and one case of compartment syndrome requiring readmission. All complications resolved.

Surgical treatment of Achilles tendon rupture can be performed safely and at less cost on an outpatient basis. Participation in this RCT has allowed us to recommend a change in the standard of care in Calgary.

The incidence of deep-vein thrombosis and the need for thromboprophylaxis following isolated trauma below the knee is uncertain. We have investigated this with a prospective randomised double-blind controlled trial using low molecular weight heparin with saline injection as placebo in patients aged between 18 and 75 years who had sustained an isolated fracture below the knee which required operative fixation. All patients had surgery within 48 hours of injury and were randomised to receive either the placebo or low molecular weight heparin for 14 days, after which they underwent bilateral lower limb venography, interpreted by three independent radiologists. Further follow-up was undertaken at two, six, eight and 12 weeks.

A total of 238 patients fulfilled all the inclusion criteria, with 127 in the low molecular weight heparin group and 111 in the placebo group, all of whom underwent bilateral venography. There was no statistically significant difference in the incidence of deep-vein thrombosis between those patients treated with low molecular weight heparin or the placebo (p = 0.22). The number of deep-vein thromboses in the two groups was 11 (8.7%) and 14 (12.6%), respectively. Age and the type of fracture were significantly associated with the rate of deep-vein thrombosis (p = 0.001 and p = 0.009, respectively) but gender, comorbidities and the body mass index were not.

The overall incidence of deep-vein thrombosis in this series was 11%. There was no clinical or statistical significant reduction in the incidence of deep-vein thrombosis with the use of thromboprophylaxis. However, we accept that owing to a cessation of funding, recruitment to this trial had to be ended prior to establishing the necessary sample size. Our results cannot, therefore, categorically exclude the possibility that low molecular weight heparin treatment could be beneficial. We recommend a further multicentre trial be undertaken to resolve this matter.